Lexapro’s Long-Term Side Effects: What You Need to Know

Lexapro (escitalopram) is widely prescribed and generally well tolerated in short-term use, but staying on it for months or years introduces a different side-effect profile than most people expect from the first few weeks. Some effects, like sexual dysfunction and emotional blunting, are common enough that researchers consider them the rule rather than the exception at longer durations. Others, like changes in bone density or low sodium levels, are rarer but carry real consequences, especially for older adults. The picture is more layered than a typical pharmacy handout suggests.

Sexual Dysfunction and Post-SSRI Sexual Dysfunction

Sexual side effects are the single most commonly reported long-term complaint with Lexapro. Reduced desire, difficulty reaching orgasm, and erectile problems show up early and, for many people, persist as long as the drug is taken. That is frustrating but expected. What has received growing attention is the possibility that sexual function does not fully bounce back after stopping the drug. This condition, known as post-SSRI sexual dysfunction (PSSD), is characterized by genital numbness, weak or pleasureless orgasm, loss of libido, and erectile dysfunction that continues after the medication has been cleared from the body.¹

The true frequency of PSSD is still debated because formal tracking has been poor. One study estimated the risk at roughly 1 in 216 patients treated with serotonergic antidepressants, and found that these drugs roughly tripled the odds of persistent erectile dysfunction even after adjusting for depression, age, and weight.² That number is small in absolute terms but far from trivial when millions of people take these medications. If your sexual function was normal before starting Lexapro and it has not recovered months after stopping, PSSD is worth raising with your prescriber rather than assuming depression itself is the cause.

Emotional Blunting and Apathy

Many long-term Lexapro users describe feeling “flattened out” emotionally. The anxiety and sadness may ease, but joy, excitement, and even caring about things that used to matter can diminish too. Researchers call this SSRI-induced indifference, and it appears to be dose-dependent: higher doses are more likely to produce it. It tends to creep in gradually, which means patients and clinicians alike can miss it or attribute it to lingering depression.³

A controlled trial comparing escitalopram with another antidepressant, agomelatine, put numbers to the problem. About 60% of patients on escitalopram reported a lack of emotional intensity, compared with 28% on agomelatine. Over half of the escitalopram group said they stopped caring about issues previously considered important, versus 16% on the other drug, despite both medications working equally well against depression itself.⁴ The leading explanation is that chronically elevated serotonin in certain brain regions dials down dopamine activity in areas linked to motivation and reward. The good news is that this blunting appears to resolve completely when the medication is stopped.³

Weight Gain

Lexapro is sometimes marketed as “weight neutral” compared with older antidepressants, but longer-term data complicates that claim. A 12-week study found that patients on escitalopram gained weight and added waist circumference. The mechanism may involve changes to a brain signaling molecule involved in appetite regulation, which decreased during treatment, potentially shifting eating behavior in ways that promote weight gain.⁵ On the reassuring side, the same study found no significant changes to cholesterol or other metabolic markers over that period, suggesting the weight gain may not immediately translate into cardiovascular risk. Whether that holds true over years of use is less certain.

Bone Health and Fracture Risk

Serotonin receptors exist on bone cells, so it has long been suspected that SSRIs might weaken the skeleton. An eight-week randomized trial of escitalopram in healthy adults found no significant change in bone-turnover markers over that short period.⁶ But short-term markers and long-term fracture risk are different questions. A large Canadian population study following people for a decade found that SSRI users had roughly 70% higher odds of experiencing a fragility fracture, and that elevated risk held even after adjusting for bone density, prior falls, and other health conditions.⁷

Animal research adds another wrinkle. In rats, escitalopram disrupted the internal structure of healing bone after a fracture, thinning the structural elements and disorganizing new tissue, even though overall bone density and strength were not dramatically altered.⁸ This raises the possibility that SSRIs do not just make fractures more likely but also slow recovery from them. For anyone over 50 or already at risk for osteoporosis, these findings are worth discussing with a doctor, especially if Lexapro use has stretched into years.

Bleeding Risk

Serotonin plays an important role in helping blood platelets clump together after an injury. Because Lexapro powerfully blocks serotonin reuptake into platelets, long-term use can thin that clotting ability. A study categorizing antidepressants by how tightly they bind the serotonin transporter found that the drugs with the highest affinity, a group that includes escitalopram, roughly doubled to tripled the odds of abnormal bleeding compared with antidepressants that bind weakly.⁹ The practical implication is that if you are also taking blood thinners, aspirin, or anti-inflammatory painkillers, the combination with Lexapro meaningfully increases the chance of gastrointestinal or other bleeding. A broader review of SSRI side effects lists prolonged overall bleeding time as one of the recognized consequences of sustained use.¹⁰

Low Sodium (Hyponatremia)

All SSRIs, Lexapro included, can trigger the body to retain too much water relative to sodium by inappropriately stimulating antidiuretic hormone. This is uncommon but potentially dangerous, especially in older adults. Case reports describe elderly patients developing severe hyponatremia, sometimes presenting with confusion or seizures, within days to weeks of starting escitalopram.¹¹ In some cases, the condition proved resistant to correction while the drug remained on board.¹² This risk is highest in women over 65, people taking diuretics, and anyone already prone to low sodium levels. Periodic blood work to check electrolytes is a reasonable precaution during long-term use in those groups.

Heart Rhythm Considerations

Lexapro has been flagged by regulators for a dose-dependent risk of QTc prolongation, a subtle change in the heart’s electrical cycle that can, in rare cases, lead to dangerous arrhythmias. Research in a real-world geriatric population, however, found no clear association between escitalopram use and QTc prolongation after adjusting for other factors, with only older age standing out as a significant risk.¹³ A separate study looking at genetic factors identified that certain gene variants, along with preexisting coronary disease, hypertension, and concurrent antipsychotic medication, significantly raised the risk of meaningful QTc changes.¹⁴ In practice, this means the heart-rhythm concern is real but concentrated among people who already have cardiac risk factors or are taking other medications that also affect QTc. For a healthy younger adult on standard doses, it is rarely a practical issue.

Movement Disorders and Restlessness

A side effect that often goes unrecognized is akathisia: an intense, inner sense of restlessness and an inability to sit still. A large pharmacovigilance analysis found that escitalopram carried roughly double the reporting odds for akathisia compared with baseline, and was also significantly associated with bruxism (involuntary teeth grinding).¹⁵ Case reports describe severe akathisia starting within days of the first dose, where patients are unable to stay seated and rate their restlessness at the highest severity level on clinical scales.¹⁶

Other movement problems reported with SSRIs as a class include dystonia (sustained involuntary muscle contractions), dyskinesia (repetitive involuntary movements), and parkinsonism-like symptoms.¹⁷ These are uncommon but tend to be misattributed to anxiety or to the underlying psychiatric condition, which delays proper management. Akathisia in particular is worth knowing about because it can be mistaken for worsening anxiety and lead to an inappropriate dose increase.

Changes to Sleep Architecture

Lexapro suppresses REM sleep, the dream-heavy stage of the sleep cycle. In animal studies, even a single dose at higher levels increased the time before the first REM period by roughly sixfold, and chronic treatment at the same dose still doubled REM latency compared with controls.¹⁸ On the other hand, chronic escitalopram treatment also smoothed out the fragmentation between REM and non-REM stages during recovery sleep and reduced awakenings.¹⁹ The net result for many users is that sleep may feel lighter or less refreshing, and vivid dreaming decreases. Whether REM suppression over years has cognitive consequences in humans remains an open question, but it is one reason some long-term users report a qualitative difference in their sleep even when the total hours look fine.

Effects on the Gut

Most of the body’s serotonin is actually produced in the gut, so it is no surprise that Lexapro affects digestion. Beyond the well-known nausea and diarrhea of the first few weeks, animal research shows that escitalopram increases intestinal permeability in the small intestine, essentially loosening the barriers that keep gut contents on the right side of the intestinal wall.²⁰ The same research found that escitalopram had antimicrobial properties, altering the composition of gut bacteria. A separate animal study linked escitalopram treatment to shifts in sphingolipid metabolism and gut microbiota composition, suggesting the drug may reshape the gut environment in ways that extend beyond transient digestive discomfort.²¹ These findings are still in early-stage research and their significance for humans on long-term treatment is not yet clear, but they hint at an underappreciated channel through which the drug affects the body.

Cognitive Function

Depression itself impairs concentration and memory, so disentangling the drug’s cognitive effects from the disease’s effects is genuinely tricky. Animal studies have shown that chronic escitalopram can restore learning and memory that had been impaired by stress, and it appears to boost the expression of BDNF, a protein important for building new connections in the hippocampus.²²²³ A human brain-imaging trial in healthy volunteers given escitalopram for about a month found preliminary evidence that longer exposure was associated with a time-dependent increase in a marker of synaptic density in the brain’s outer cortex, though the overall group comparison did not reach statistical significance.²⁴

Despite those encouraging signals, a broader literature review notes that some degree of cognitive impairment is reported alongside emotional blunting during long-term SSRI use.¹⁰ The picture that emerges is nuanced: Lexapro likely protects against the cognitive damage caused by depression itself but may introduce its own subtle dulling in some people, especially at higher doses.

Discontinuation Syndrome

Stopping Lexapro after long-term use can itself be a medical event. In a preliminary study of patients discontinuing escitalopram, over half developed antidepressant discontinuation syndrome. The most frequent symptoms were dizziness, muscle tension, chills, confusion, memory problems, and bouts of crying.²⁵ Patients who had been on higher doses and had higher drug levels in their blood were significantly more likely to experience these symptoms. In rare cases involving people who metabolize the drug unusually slowly, discontinuation syndrome can be protracted, lasting weeks or months.²⁶ This is one reason gradual tapering under medical supervision is strongly recommended, and why the decision to start Lexapro should factor in the possibility that stopping later may not be straightforward.

There is also the separate question of tolerance: whether the drug loses effectiveness over time. Some researchers have described antidepressants inducing tolerance phenomena in certain patients, where the original therapeutic effect fades and higher doses or medication switches become necessary.²⁷ This is sometimes called “antidepressant poop-out” in informal clinical parlance and, while not universal, is a recognized long-term concern.

Pregnancy Considerations

For people of reproductive age, the question of whether Lexapro is safe during pregnancy is practically inevitable. A large register-based study found that children whose mothers continued antidepressants during pregnancy had a modestly higher risk of developing affective disorders themselves. However, the same study found a nearly identical increase in risk when fathers continued antidepressants during the pregnancy period, even though the father’s pills have no direct chemical path to the fetus. That strongly suggests the association is driven by the parents’ underlying mental-health conditions being passed on, not by the drug itself crossing the placenta.²⁸

A prospective study looking at children at age two and a half found small but measurable differences in cognitive and motor development between SSRI-exposed and unexposed children, though the motor difference lost significance once the severity of the mother’s anxiety was accounted for.²⁹ A broader analysis in JAMA Internal Medicine found no meaningful increase in the risk of neurodevelopmental disorders for most SSRIs, but noted that escitalopram specifically had slightly higher adjusted hazard ratios across several outcomes than other drugs in the class, though the authors stopped short of calling this conclusive.³⁰ The honest answer is that stopping Lexapro to avoid potential fetal exposure must be weighed against the well-documented risks of untreated depression during pregnancy, and that decision is best made with an obstetrician and psychiatrist together.

Hair Loss

This is not on most prescribers’ radar, but scattered case reports link escitalopram to diffuse hair loss. In one well-documented case, a woman developed noticeable thinning after starting the drug, saw it resolve after stopping, and then watched it return when she restarted escitalopram. Switching to a different antidepressant class did not cause the hair loss to recur.³¹ The frequency of this side effect is unknown, but if you are experiencing unexplained shedding while on Lexapro, the medication is worth considering as a possible contributor.

Eye Health

An analysis of the FDA’s adverse-event reporting database found that escitalopram was significantly associated with higher reporting odds for acute angle-closure glaucoma compared with a control drug. The reporting odds ratio was notably high among the antidepressants studied.³² Pharmacovigilance databases have well-known limitations: they capture what people report, not necessarily what the drug causes. Still, the signal is strong enough that people with narrow-angle anatomy or a family history of glaucoma should mention their Lexapro use to their eye doctor. Pupil dilation, which SSRIs can cause, is the suspected mechanism, because it can block fluid drainage in susceptible eyes.

How Lexapro Compares to Other SSRIs

Lexapro is often positioned as the best-tolerated SSRI, and the comparative evidence broadly supports that framing. A review comparing it with paroxetine and sertraline concluded that escitalopram had a more favorable tolerability profile, with fewer drug-interaction issues than sertraline and less anticholinergic activity than paroxetine.³³ But “best tolerated in the class” does not mean free of long-term effects. A comprehensive review pointed out that while short-term trials consistently paint SSRIs as safe, longer naturalistic and pharmacovigilance studies reveal a more complex set of side effects than the clinical-trial data alone would suggest.³⁴ This gap is partly a design issue: most randomized trials of antidepressants run for eight to twelve weeks, whereas patients routinely take the medication for years. The long-term side-effect profile is therefore pieced together from observational studies, case series, and pharmacovigilance data rather than the gold-standard trials that established the drug’s efficacy.